1. Scrip
  2. >>Business

Roche Could Have The Best Obesity Pill

 
• By Elizabeth Cairns

That is, if very early data in a handful of patients are borne out in later, larger studies.    

Pills and dollars

The data are early both in terms of trial stage and time point, but Roche Holding AG’s newly acquired CT-996 looks like it might be the most effective obesity pill yet. The GLP-1 agonist, which Roche got when it bought Carmot Therapeutics Inc. for $2.7bn in December, looks more effective even than Viking Therapeutics, Inc.’s VK2735 – though this asset is more advanced.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

 
• By Dexter Jie Yan

Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.

Roivant Tightens Leadership Grip On Immunovant, Narrows Near-Term IMVT-1402 Focus

 
• By Mandy Jackson

Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.

Alis Biosciences Launches To Free Cash From Stalled-Out Biotechs

 
• By Mandy Jackson

As investors have begun to ask troubled drug developers to suspend operations and return remaining cash to shareholders, Alis has stepped forward with a new fund aiming to facilitate that.